Psychotropic medication use in youth at high risk for psychosis: Comparison of baseline data from two research cohorts 1998–2005 and 2008–2011
Open accessThe DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Background Antipsychotic medication use rates have generally been rising among youth with psychiatric disorders, but little is known about use rates of antipsychotics or other psychotropic medications in patients at high risk for psychosis. Method Baseline psychotropic medication use rates were compared in two research cohorts of patients at high risk for psychosis that enrolled between 1998-2005 (n=391) and 2008-2011 (n=346). Treatment durations and antipsychotic doses were described for cohort 2. Results Median age was 17 years in cohort 1 and 18 years in cohort 2. The rate of prescription of any psychotropic at baseline was roughly 40% for each cohort. Antipsychotic prescription rates were 24% among sites that permitted baseline antipsychotic use in cohort 1 and 18% in the cohort 2; the decline did not quite reach statistical significance (p=0.064). In cohort 2 the mean±sd baseline chlorpromazine-equivalent dose was 121±108 mg/d, and lifetime duration of antipsychotic treatment was 3.8±5.9 months. Discussion Although the rate of antipsychotic prescription among high-risk youth may have fallen slightly, the nearly one-in-five rate in the second cohort still constitutes a significant exposure. Mitigating factors were that doses and durations of treatment were low. As for other nonpsychotic conditions, it is incumbent on our field to develop alternative treatments for high-risk patients and to generate additional evidence for or against the efficacy of antipsychotics to help define their appropriate role if alternative treatments fail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Psychosis High-Risk State: A Comprehensive State-of-the-Art Review
Fusar-Poli, P., Borgwardt, S., Bechdolf, A., Addington, J., Riecher-Rössler, A., Schultze-Lutter, F., Keshavan, M., Wood, S., Ruhrmann, S., Seidman, L. J., et al. (2013) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2013.269 · Cited by 1,483 · cited 2×
“, 2009) is a non-psychotic condition under increasing investigation over the past two decades (Fusar-Poli et al., 2013; Klosterkoetter et al., 2011).”
BackgroundSelf-citationPredicting Psychosis: Meta-analysis of Transition Outcomes in Individuals at High Clinical Risk
Fusar-Poli, P. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1472 · Cited by 1,361
The Prodromal Phase of First-episode Psychosis: Past and Current Conceptualizations
Yung, A. R., & McGorry, P. D. (1996) · Schizophrenia Bulletin · doi:10.1093/schbul/22.2.353 · Cited by 1,168 · cited 2×
“Also known by other names including ‘at-risk mental state’ and ‘ultra-high-risk’, the risk syndrome is based on earlier retrospective observations of subsyndromal or “attenuated” positive symptoms in the months or years preceding frank onset of schizophrenia (Yung and McGorry, 1996a).”
BackgroundMcGorry, P. D., Yung, A. R., Phillips, L. J., Yuen, H. P., Francey, S., Cosgrave, E. M., Germano, D., Bravin, J., McDonald, T., Blair, A., et al. (2002) · Archives of General Psychiatry · doi:10.1001/archpsyc.59.10.921 · Cited by 1,056 · cited 2×
“Medication treatment studies have primarily focused on antipsychotics (McGlashan et al., 2006; McGorry et al., 2002; Ruhrmann et al., 2007; Woods et al., 2003; Woods et al., 2007; Yung et al., 2011) but have also included a search for alternative treatments with fewer adverse effects (Amminger et al.”
BackgroundCorrell, C. U. (2009) · JAMA · doi:10.1001/jama.2009.1549 · Cited by 1,050 · cited 2×
“Although the rate of aripiprazole prescription in NAPLS-1 was limited by its late 2002 approval toward the end of cohort accrual, we speculate that these changes suggest community prescribers may have been seeking to reduce metabolic risks of prescription in these patients, since aripiprazole is generally regarded as…”
BackgroundAmminger, G. P., Schäfer, M. R., Papageorgiou, K., Klier, C. M., Cotton, S. M., Harrigan, S. M., Mackinnon, A., McGorry, P. D., & Berger, G. E. (2010) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.192 · Cited by 896
Cognitive Functioning in Prodromal Psychosis: A Meta-analysis
Fusar-Poli, P., Deste, G., Smieskova, R., Barlati, S., Yung, A. R., Howes, O., Stieglitz, R.-D., Vita, A., McGuire, P., & Borgwardt, S. (2012) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.1592 · Cited by 691 · cited 2×
“A recent meta-analysis of 27 studies suggested that the average prospective rate of transition to frank psychosis is 22% by one year and 36% by three years (Fusar-Poli et al., 2012a).”
BackgroundMaher, A. R., Maglione, M., Bagley, S., Suttorp, M., Hu, J.-H., Ewing, B., Wang, Z., Timmer, M., Sultzer, D., & Shekelle, P. G. (2011) · JAMA · doi:10.1001/jama.2011.1360 · Cited by 558 · cited 2×
“Antipsychotic use has been rising in adult patients also (Alexander et al., 2011; Maher et al., 2011), but the increase may be of especial concern in youth since metabolic adverse effects appear even more frequent in young patients (Gebhardt et al., 2009; Kryzhanovskaya et al., 2012; Safer, 2011;…”
BackgroundMcGlashan, T. H., Zipursky, R. B., Perkins, D., Addington, J., Miller, T., Woods, S. W., A. Hawkins, K., E. Hoffman, R., Preda, A., Epstein, I., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.5.790 · Cited by 556 · cited 4×
“Medication treatment studies have primarily focused on antipsychotics (McGlashan et al., 2006; McGorry et al., 2002; Ruhrmann et al., 2007; Woods et al., 2003; Woods et al., 2007; Yung et al., 2011) but have also included a search for alternative treatments with fewer adverse effects (Amminger et al.”
BackgroundSelf-citationEarly interventions to prevent psychosis: systematic review and meta-analysis
Stafford, M. R., Jackson, H., Mayo-Wilson, E., Morrison, A. P., & Kendall, T. (2013) · BMJ · doi:10.1136/bmj.f185 · Cited by 456 · cited 4×
“, 2012), it is incumbent on our field to develop alternative treatments for high-risk patients (Amminger et al., 2010; Stafford et al., 2013) and also to generate additional evidence for or against the efficacy of antipsychotics in highrisk patients to define their appropriate role if alternative treatments fail.”
BackgroundInfluential
Cited by
Anticevic, A., Haut, K., Murray, J. D., Repovs, G., Yang, G. J., Diehl, C., McEwen, S. C., Bearden, C. E., Addington, J., Goodyear, B., et al. (2015) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2015.0566 · Cited by 379
Self-citationPruessner, M., Cullen, A. E., Aas, M., & Walker, E. F. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2016.12.013 · Cited by 315
Self-citationA critique of the “ultra‐high risk” and “transition” paradigm
van Os, J., & Guloksuz, S. (2017) · World Psychiatry · doi:10.1002/wps.20423 · Cited by 261
Seidman, L. J., Shapiro, D. I., Stone, W. S., Woodberry, K. A., Ronzio, A., Cornblatt, B. A., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., et al. (2016) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2016.2479 · Cited by 270
Self-citationPerkins, D. O., Jeffries, C. D., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., McGlashan, T. H., Seidman, L. J., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbu099 · Cited by 238
Self-citationSpecificity of Incident Diagnostic Outcomes in Patients at Clinical High Risk for Psychosis
Webb, J. R., Addington, J., Perkins, D. O., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Heinssen, R. K., Seidman, L. J., Tarbox, S. I., et al. (2015) · Schizophrenia Bulletin · doi:10.1093/schbul/sbv091 · Cited by 77
Self-citationFusar-Poli, P., Frascarelli, M., Valmaggia, L., Byrne, M., Stahl, D., Rocchetti, M., Codjoe, L., Weinberg, L., Tognin, S., Xenaki, L., et al. (2015) · Psychological Medicine · doi:10.1017/s003329171400244x · Cited by 73
“The North American study also found that patients with co-morbid depression were prescribed more ADs in the community (Woods et al. 2013).”
BackgroundResultLaurens, K. R., & Cullen, A. E. (2016) · Social Psychiatry and Psychiatric Epidemiology · doi:10.1007/s00127-015-1151-x · Cited by 59
Metadata
- Authors
- Woods, S. W., Addington, J., Bearden, C. E., Cadenhead, K. S., Cannon, T. D., Cornblatt, B. A., Mathalon, D. H., Perkins, D. O., Seidman, L. J., Tsuang, M. T., Walker, E. F., & McGlashan, T. H.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 148
- Issue
- 1-3
- Pages
- 99-104
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2084802730
- Cited by
- 40
- References
- 12
- FWCI
- 3.83
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.